Scrip Podcasts

Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 28, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Zi...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月21日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Moderna的mRNA候选药物在黑色素瘤治疗方面取得突破；Enhertu在肺癌治疗方面取得胜利；衡量行业研发生产力；Enveda的GLP-1后继候选药物；以及中国崛起的背后因素。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-liste...

Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 21, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—melanoma win for Moderna's mRNA candidate; lung cancer victory for Enhertu; measuring industry R&D productivity; Enveda's post-GLP-1 contender; and the factors behind China's rise. Story links: h...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月14日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 全球特发性肺纤维化（IPF）研发管线概览；武田制药的嗜睡症药物获美国批准；Arrowhead公司探讨严重高甘油三酯血症治疗方案的差异化；SMID公司第二季度进展；以及Attruby在伴有心肌病变的转甲状腺素蛋白介导的淀粉样变性中的定位。 Story link: https://insights.citeli...

Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 14, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—a look at the global IPF pipeline; US approval for Takeda's narcolepsy drug; Arrowhead talks differentiation in severe hypertriglyceridemia; SMID Q2 developments; and Attruby positioning in trans...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月7日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 诺和诺德考虑进行补充性收购；拜耳抨击德国定价政策；尽管Foundayo表现不佳，礼来股价仍大幅上涨；欧洲生物技术企业力求实现跨越式发展；以及对阿斯利康与百时美施贵宝在亚太地区潜在合并的展望。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-fiv...

Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 7, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—Novo Nordisk weighs bolt-on deals; Bayer slams Germany pricing; Lilly soars despite Foundayo struggles; European biotech wants to leapfrog; and a look at the potential AstraZeneca/BMS combination...

China has become an increasingly important part of global clinical development, with sponsors considering the region earlier than ever before as part of their broader development strategies. In this episode, Meredith Landry, Managing Editor of Citeline's Custom Content, speaks with Catherine Xu, Senior Operations Manager at Novotech, about the factors reshaping China's role in global clinical deve...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月31日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 阿斯利康收紧人工智能支出；Argenx的产品管线聚焦产品开发；葛兰素史克在推进III期临床试验计划的同时削减成本；赛诺菲对产品管线进行重新评估；以及中国业务新公司2.0版。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/qu...

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 31, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—AstraZeneca reins in AI spending; Argenx’s pipeline in a product play; GSK cutting costs amid Phase III plans; Sanofi’s pipeline reckoning; and NewCo version 2 for Chinese assets. Story links: ht...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月24日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 诺和诺德在肥胖症治疗领域起诉礼来；特朗普针对仿制药采取新的关税措施；诺华CEO称赞日本、抨击德国的定价政策；制药行业会迎来“稀土时刻”吗？；以及欧洲生物技术行业正处于十字路口。 Story/video links: https://insights.citeline.com/scrip/podcasts/scrips-five-m...

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 24, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—Novo Nordisk sues Lilly in obesity battle; Trump takes new tariff action on generics; Novartis CEO praises Japan, blasts Germany on pricing; could pharma have a rare earth moment?; and European b...

This Scrip video podcast brings together three European biotech leaders to discuss the challenges facing the sector, and what measures are needed to stop it falling behind the US and China and to create the next generation of European biotech champions.

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 17, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—J&J ups guidance; Gilead’s acquisition strategies; Bayer breakup rumors; Biogen’s Alzheimer’s results; and an interview with Lilly’s blood test pioneer.  Story links: https://insights.citeli...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月17日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 强生上调业绩预期；吉利德的收购策略；拜耳拆分传闻；百健的阿尔茨海默病研究结果；以及对礼来血液检测先驱的专访。 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

Denali CEO Ryan Watts talks about the company's TransportVehicle platform and how it can open up delivery of a wide range of drug cargoes into the brain. Its first approved therapy is Avlayah for Hunter Syndrome, with tau and beta-amyloid targeting assets for Alzheimer's in development.

Eisai's Michael Irizarry talks to Scrip about broadening Leqembi's use with its subcutaneous version, its ongoing Phase III in treating patients before dementia symptoms appear and news from a Phase II study of it tau-targeting asset, etalanetug.

On the July 2026 edition of the Scrip Deals Podcast, Scrip Senior Writer Joseph Haas and Bruce Leuchter, CEO of Neurvati Biosciences and GRIN Therapeutics, discussed the recent trend of biopharma M&A deals valued at $1bn or greater closing quickly. Recent research showed that closing time for such deals is less than half of how long it took to close a billion-dollar acquisition during the span on...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月10日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Vertex收购Crinetics；阿斯利康III期试验失败；强生公司的并购重点；伊普森（Ipsen）的“寻宝”之旅；以及Dyne首席执行官谈战略。 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 10, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–Vertex's Crinetics deal; AstraZeneca's Phase III fail; J&J's deal focus; Ipsen's search for diamonds; and Dyne's CEO on strategy. Story links: https://insights.citeline.com/scrip/podcasts/scrips-...

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 3, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–later stage assets help fundraising; dealmaking surges this year; Amgen’s approach to AI; Takeda’s AI strategy; and Anthropic launches Claude Science. Story links: https://insights.citeline.com/sc...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月03日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 后期阶段资产助力融资；今年并购活动激增；安进（Amgen）对 AI的策略；武田（Takeda）的AI战略；以及Anthropic推出Claude Science。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-thi...

As global clinical development strategies evolve, Europe is emerging as a critical hub for scientific innovation, operational agility, and patient recruitment — reshaping its role in the future of clinical trials. In this episode, Scott Davis, Vice President of Clinical Services at Novotech, joins Andrew Warmington from Citeline to explore how sponsors are rethinking Europe’s place in global devel...

Ovid Therapeutics Chairman Jeremy Levin talks with Scrip about how the US should view its biotech sector as a strategic national asset and urges the venture capital sector to place more emphasis on supporting early and innovative science.